Obalon Therapeutics, Inc. (OBLN) financial statements (2020 and earlier)

Company profile

Business Address 5421 AVENIDA ENCINAS
SAN DIEGO, CA 92008
State of Incorp. DE
Fiscal Year End December 31
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments14244475
Cash and cash equivalents14212173
Short-term investments 3233
Receivables0141
Inventory, net of allowances, customer advances and progress billings2211
Inventory2211
Other current assets2221
Total current assets:18295278
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment1211
Total noncurrent assets:2211
TOTAL ASSETS:20305379
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1561
Accounts payable111 
Accrued liabilities   1
Employee-related liabilities1442
Interest and dividends payable   0
Other undisclosed accounts payable and accrued liabilities   (3)
Deferred revenue0
Debt1102 
Deferred revenue and credits1 
Other liabilities2221
Other undisclosed current liabilities 0 3
Total current liabilities:417105
Noncurrent Liabilities
Long-term debt and lease obligation1 810
Long-term debt, excluding current maturities  810
Operating lease, liability1
Liabilities, other than long-term debt 00 
Deferred revenue and credits0 
Deferred rent credit 0
Total noncurrent liabilities:10810
Total liabilities:5171814
Stockholders' equity
Stockholders' equity attributable to parent16133564
Common stock0000
Additional paid in capital188162146141
Accumulated other comprehensive loss  (0)(0)
Accumulated deficit(172)(149)(111)(77)
Total stockholders' equity:16133564
TOTAL LIABILITIES AND EQUITY:20305379

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues39103
Revenue, net103
Cost of revenue(3)(5)(5)(3)
Gross profit:0451
Operating expenses(24)(41)(39)(20)
Operating loss:(23)(37)(34)(20)
Nonoperating expense
(Other Nonoperating expense)
(0)(0)(0)(0)
Net loss:(23)(37)(35)(20)
Other undisclosed net loss attributable to parent(0)(0)(0)(1)
Net loss available to common stockholders, diluted:(24)(37)(35)(20)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(23)(37)(35)(20)
Other comprehensive income (loss) 0(0)(0)
Comprehensive loss:(23)(37)(35)(20)
Other undisclosed comprehensive loss, net of tax, attributable to parent(0)(0)(0)(1)
Comprehensive loss, net of tax, attributable to parent:(24)(37)(35)(20)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: